KOSPIApparel & Living005820

Wonlim

₩13,070▲ 0.15%2026-11-18 close
Market Cap
₩30B
Turnover
₩12,571,650
Volume
964 shares
Shares out.
2.3M
PER
9.1×
PBR
0.2×
EPS
₩1,429
Dividend Yield
3.52%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩460 per share · Prices as of the 2026-11-18 close

01

Report overview

Packaging Core and Medical Subsidiary Diverge

Wonlim pairs a core industrial packaging business with medical device and venture investment subsidiaries, and its quarterly profit turned to an operating loss in the third quarter of 2026.

  1. 1

    Revenue in 2025 was KRW 89.7 billion, the largest year in 2022 to 2025, and operating profit was KRW 4.43 billion, up 155.3% year on year.

  2. 2

    Net income attributable to controlling shareholders peaked at KRW 7.36 billion in 2023, then declined for two straight years to KRW 3.73 billion in 2025.

  3. 3

    In the third quarter of 2026 the company posted an operating loss of KRW 187 million and a net loss attributable to controlling shareholders of KRW 392 million.

  4. 4

    Press reports said the medical device subsidiary's first-half 2026 revenue rose 12% to KRW 18.3 billion and operating profit rose 53% to KRW 2.4 billion.

  5. 5

    At the regular shareholders meeting on March 26, 2026, a cash dividend for fiscal 2025 was approved and solar power generation was added to the business purpose.

02

Business structure

Wonlim was founded in 1968 as a maker of industrial packaging and listed on the KOSPI market in 1990. Its segments in the second quarter of 2026 were packaging at 53 percent of revenue, medical device wholesale at 43 percent, financial investment at 2 percent and leasing at 1 percent.

The packaging core is PP and PE bags, and a corporate monitoring report puts its share of the domestic market for these products at 60 percent. Packaging sales were reported to have improved as resin prices stayed stable and the domestic bag market shifted toward higher-grade materials and better printed designs.

The medical device segment runs through the subsidiary that supplies orthopedic devices and the MAKO robotic joint surgery system, building on its domestic distribution of Stryker products. Its sales network has expanded from the Seoul metropolitan area into Gangwon and Gyeongsang provinces.

The financial investment segment is run by a venture capital subsidiary that the company says is expanding its portfolio in deep tech fields such as artificial intelligence.

Packaging is a traditional manufacturing business while medical devices draw on demand from an aging population, so the drivers of consolidated results differ by segment. Consolidated results reflect the performance of both subsidiaries.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩21B₩1.4B6.8%
2025Q4₩27.5B₩1.4B5.1%
2026Q1₩20.7B₩1.2B5.9%
2026Q2₩22.3B₩800M3.5%
2026Q3₩19.7B-₩200M−0.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩81.9B₩3.4B₩7.2B4.2%6.3%18.1%
2023₩84.4B₩5.1B₩7.4B6.0%6.1%15.2%
2024₩82.4B₩1.7B₩4B2.1%3.3%19.3%
2025₩89.7B₩4.4B₩3.7B4.9%2.9%19.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 81.9 billion in 2022, KRW 84.4 billion in 2023 (up 3.0% year on year), KRW 82.4 billion in 2024 (down 2.4%) and KRW 89.7 billion in 2025 (up 8.9%), with 2025 the largest year in the 2022 to 2025 range.

Operating profit moved from KRW 3.4 billion in 2022 to KRW 5.07 billion in 2023 (up 49.0%), then fell to KRW 1.73 billion in 2024 (down 65.8%) and recovered to KRW 4.43 billion in 2025 (up 155.3%). Operating margin was 4.2 percent in 2022, 6.0 percent in 2023, 2.1 percent in 2024 and 4.9 percent in 2025.

Net income attributable to controlling shareholders rose to KRW 7.36 billion in 2023 before falling 45.2 percent to KRW 4.03 billion in 2024 and 7.6 percent to KRW 3.73 billion in 2025, a two-year decline.

Over the same period, net income including non-controlling interests rose from KRW 4.84 billion in 2024 to KRW 5.18 billion in 2025, so the two measures moved in opposite directions in 2025.

Operating cash flow was KRW 8.86 billion in 2022, KRW 8.48 billion in 2023, KRW 10.3 billion in 2024 and KRW 4.84 billion in 2025.

The debt ratio was 19.3 percent at the end of 2025, with total equity of KRW 159.1 billion, of which KRW 126.6 billion belongs to controlling shareholders, and total liabilities of KRW 30.8 billion.

Quarterly revenue reached KRW 27.5 billion in the fourth quarter of 2025, the highest of the last five quarters, then fell to KRW 20.7 billion, KRW 22.3 billion and KRW 19.7 billion in the first three quarters of 2026.

Operating profit slid from KRW 1.43 billion in the third quarter of 2025 and KRW 1.41 billion in the fourth quarter to KRW 1.22 billion and KRW 789 million in the first two quarters of 2026, then turned into an operating loss of KRW 187 million in the third quarter.

Net income attributable to controlling shareholders also swung to a loss of KRW 392 million in the third quarter of 2026.

First-half 2026 results were reported as revenue of KRW 43 billion (up 4.3 percent) and operating profit of KRW 2 billion (up 26.4 percent), which matches the sum of the disclosed first and second quarter figures.

Net income attributable to controlling shareholders for the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 2.94 billion.

05

Industry analysis

Conditions in the packaging business depend on the price of PP and PE resin, the main raw materials. A corporate monitoring report said resin prices were stable in the year-to-date period through the third quarter of 2025, which it cited as a driver of higher sales, a sign that cost pressure had eased.

If resin prices rise again, margins come under pressure, so whether the third-quarter 2026 operating loss reflected cost factors is a variable to watch. In the domestic bag market, higher-grade materials and better printing design are supporting demand.

The 60 percent domestic share cited for the packaging business suggests a firm position, but the year-by-year trend in market size and share lies outside the disclosed data and needs to be checked against separate sources.

The medical device segment sits on rising demand for joint replacement surgery as the population ages, according to the same monitoring report. The subsidiary has widened its sales network on the back of distribution agreements for Stryker and Tornier shoulder products.

The financial investment segment is moving toward deep tech areas such as artificial intelligence, and its investment returns can swing widely with market conditions.

Because Wonlim's consolidated results combine packaging, medical devices and investments, general indicators for the textile and fashion sector are of limited use for comparison. Most listed companies in the same sector classification focus on apparel or fashion, so their business structures differ considerably.

06

Outlook

In its first-half 2026 results announcement, the company said it would keep pursuing cost and expense efficiency in its industrial packaging business through the second half. It also planned to strengthen its growth base by expanding new hospital and customer relationships and managing its investment portfolio.

The medical device subsidiary was reported to have posted first-half 2026 revenue of KRW 18.3 billion and operating profit of KRW 2.4 billion, with new accounts at large general hospitals and orthopedic specialty hospitals contributing to results.

Improved investment returns at the venture capital subsidiary also added to consolidated earnings. At the regular shareholders meeting on March 26, 2026, solar power generation was added to the business purpose, and the company said the aim is to produce and sell electricity from solar facilities at its plant.

A patent acquisition was disclosed voluntarily on September 7, 2026. The company runs an ESG innovation task force reporting directly to the chief executive, with expanding its eco-friendly product portfolio and strengthening occupational safety among its priorities.

The outlook it has presented centers on qualitative goals such as cost efficiency, customer expansion and investment management. With an operating loss disclosed for the third quarter of 2026, how second-half cost efficiency shows up in quarterly profit is the next point to check. A sustainability report due to be published at year-end will also show progress on the ESG agenda.

07

Valuation

PER
9.1×
PBR
0.2×
ROE
2.3%
EPS
₩1,429
BPS
₩61,965
Dividend per share
₩460

The price-to-book ratio sits well below 1 times, and the current market capitalization is smaller than the KRW 126.6 billion of equity attributable to controlling shareholders at the end of 2025.

Trading at a low multiple against book value does not by itself imply an earnings recovery, and the direction of earnings is the central question for this stock.

With net income attributable to controlling shareholders down for two straight years and a net loss in the third quarter of 2026, the low multiple can be read as the market reflecting the decline in earnings.

On the other side, a cash dividend for fiscal 2025 was approved at the March 2026 shareholders meeting, and a Korean business daily reported that the company received a high-dividend company certification.

The same report said the company had been profitable every year for the past five years, and the third-quarter 2026 loss runs in the opposite direction. A high share held by the largest shareholder side, which leaves a low free float, is another factor in reading the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Growth in the medical device subsidiary

The subsidiary was reported to have lifted first-half 2026 revenue 12 percent to KRW 18.3 billion and operating profit 53 percent to KRW 2.4 billion. Its orthopedic devices and MAKO systems, along with new hospital accounts, contributed to these results.

Medical devices account for 43 percent of revenue in the second quarter of 2026, so growth in this unit feeds directly into overall profit.

Packaging share and stable input costs

A corporate monitoring report puts the domestic market share of its PP and PE bag products at 60 percent. Through the third quarter of 2025, stable resin prices and higher-grade materials were recorded as lifting sales. The packaging business has also kept annual revenue in a fairly stable range from 2022 to 2025.

Financial capacity and shareholder returns

Total liabilities at the end of 2025 were KRW 30.8 billion against total equity of KRW 159.1 billion, with a debt ratio of 19.3 percent. A cash dividend for fiscal 2025 was approved at the March 2026 shareholders meeting. A Korean business daily reported high-dividend certification and annual profits over the past five years.

09

Bear factors

Quarterly profit has turned to losses

Operating profit fell from KRW 1.43 billion in the third quarter of 2025 to KRW 789 million in the second quarter of 2026 and then turned into an operating loss of KRW 187 million in the third quarter. Net income attributable to controlling shareholders swung to a loss of KRW 392 million in the same quarter. Revenue of KRW 19.7 billion fell 6.0 percent year on year as profit deteriorated.

Weaker operating cash flow

Operating cash flow fell from KRW 10.3 billion in 2024 to KRW 4.84 billion in 2025. Operating profit in the same year rose 155.3 percent to KRW 4.43 billion, yet cash generation declined. The divergence between profit and cash flow is a reason to examine the quality of earnings.

Two straight years of lower controlling-shareholder profit

Net income attributable to controlling shareholders declined from KRW 7.36 billion in 2023 to KRW 4.03 billion in 2024 and KRW 3.73 billion in 2025. In 2025 net income including non-controlling interests rose while the controlling-shareholder share fell. Revenue dropped 2.4 percent in 2024, and operating margin slid from 6.0 percent in 2023 to 2.1 percent in 2024.

10

Risk factors

Reliance on subsidiaries and investment gains

Consolidated results depend heavily on the medical device and venture investment subsidiaries. Investment gains can swing with market conditions, and the pace of new accounts also affects the medical device business. If either unit slows, a recovery in packaging alone may not be enough to support total profit.

Raw material costs and packaging margins

The packaging business is sensitive to PP and PE resin prices. Sales improved through the third quarter of 2025 with stable resin prices, but a rise in input costs could compress margins. The causes of the third-quarter 2026 operating loss need to be separated into cost factors and other factors.

Concentrated ownership and limited free float

A corporate monitoring report puts the largest shareholder side at about 60 percent, which leaves a small free float. A change report filed on August 24, 2026 recorded a decrease of 360,000 shares for the representative director's holdings. A limited free float can affect share price volatility and trading liquidity.

11

What to watch next

  1. Late December 2026

    Sustainability report due for publication — shows progress on the ESG task force's eco-friendly portfolio and occupational safety agenda.

  2. End of March 2027 (90-day deadline after fiscal year-end)

    Filing of the 2026 annual business report — the full-year revenue, operating profit, net income attributable to controlling shareholders and fourth-quarter results, and how the annual operating margin compares with 4.9 percent in 2025.

  3. March 2027

    2027 regular shareholders meeting — confirms the cash dividend decision for fiscal 2026 and any change to the business purpose. The 2026 meeting was held on March 26.

  4. May 2027

    First-quarter 2027 quarterly report — shows whether quarterly operating profit returns to positive territory after the third-quarter 2026 operating loss.

12

Overall view

Wonlim is a company whose core is industrial packaging, extended into medical devices and venture investment through subsidiaries. Among annual results for 2022 to 2025, revenue was largest in 2025, and operating profit recovered to KRW 4.43 billion in 2025 after bottoming in 2024.

Net income attributable to controlling shareholders, by contrast, peaked in 2023 and fell for two straight years in 2024 and 2025. Quarterly revenue in 2026 ranged between KRW 19.7 billion and KRW 22.3 billion, and operating profit turned into a KRW 187 million loss in the third quarter, breaking the trend.

Strengths include growth at the medical device subsidiary, the packaging market share, the dividend approved for fiscal 2025 and the room provided by the capital structure. Weaknesses include the quarterly swing to losses, lower operating cash flow and two years of lower controlling-shareholder net income.

The valuation sits low against book value, yet the low multiple can also be read as reflecting the earnings decline, so whether earnings recover is the central point.

The next checkpoint is the 2026 annual business report, where fourth-quarter results and the full-year operating margin will be compared with 4.9 percent in 2025.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. butler.works
  2. accidentalorder.com
  3. comp.wisereport.co.kr
  4. news.nate.com
  5. markets.hankyung.com
  6. edaily.co.kr
  7. edaily.co.kr
  8. newstap.co.kr
  9. edaily.co.kr
  10. m.news.nate.com
  11. newspim.com
  12. m.news.nate.com
  13. news.nate.com
  14. m.news.nate.com
  15. kpinfo.kr
  16. denews.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis